Currently, there are 393.95M common shares owned by the public and among those 391.00M shares have been available to trade.
The company’s stock has a 5-day price change of -0.58% and -24.78% over the past three months. NOV shares are trading -24.11% year to date (YTD), with the 12-month market performance down to -19.42% lower. It has a 12-month low price of $14.98 and touched a high of $21.23 over the same period. NOV has an average intraday trading volume of 3.79 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.08%, -6.46%, and -14.74% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of NOV Inc (NYSE: NOV) shares accounts for 97.27% of the company’s 393.95M shares outstanding.
It has a market capitalization of $6.06B and a beta (3y monthly) value of 1.67. The stock’s trailing 12-month PE ratio is 5.69, while the earnings-per-share (ttm) stands at $2.70. The company has a PEG of 0.18 and a Quick Ratio of 1.65 with the debt-to-equity ratio at 0.37. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.19% over the week and 2.47% over the month.
Earnings per share for the fiscal year are expected to decrease by -36.35%, and 8.70% over the next financial year.
Looking at the support for the NOV, a number of firms have released research notes about the stock. TD Cowen stated their Buy rating for the stock in a research note on Oct-29-24, with the firm’s price target at $28-$22. Wells Fargo coverage for the NOV Inc (NOV) stock in a research note released on September 25, 2024 offered a Underweight rating with a price target of $16. TD Cowen was of a view on July 29, 2024 that the stock is Buy, while TD Cowen gave the stock Buy rating on April 29, 2024, issuing a price target of $27- $26. TD Cowen on their part issued Outperform rating on February 05, 2024.
